ImmuPharma logo

IMM - ImmuPharma Share Price

16p 0.6  3.6%

Last Trade - 21/02/20

Sector
Healthcare
Size
Micro Cap
Market Cap £26.8m
Enterprise Value £24.6m
Revenue £19.6k
Position in Universe 1320th / 1838
Bullish
Bearish
Unlock IMM Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

IMM Revenue Unlock IMM Revenue

Net Income

IMM Net Income Unlock IMM Revenue

Normalised EPS

IMM Normalised EPS Unlock IMM Revenue

PE Ratio Range

IMM PE Ratio Range Unlock IMM Revenue

Dividend Yield Range

IMM Dividend Yield Range Unlock IMM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
IMM EPS Forecasts Unlock IMM Revenue
Profile Summary

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated February 21, 2000
Public Since October 28, 2003
No. of Shareholders: n/a
No. of Employees: 11
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 167,360,920
Free Float (0.0%)
Eligible for
ISAs
SIPPs
IMM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for IMM
Upcoming Events for IMM
Similar to IMM
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.